Stoke Therapeutics (STOK) Director Edward Kaye MD Sells Shares

What Happened

• Dr. Edward M. Kaye, a director of Stoke Therapeutics (STOK), had 26,250 shares issued on August 14, 2026 upon settlement/conversion of performance stock units (PSUs). An issuer-mandated sale of 26,250 shares occurred to satisfy tax withholding related to that vesting.
• On August 18, 2026 he sold 11,930 shares in the open market at a weighted average price of $32.01 (proceeds reported $381,846) and 637 shares at a weighted average price of $32.47 (proceeds reported $20,682). Combined open-market proceeds ≈ $402,528.
• These transactions are sales (not purchases); the PSU settlement and the issuer-mandated sale reflect compensation vesting and routine tax withholding rather than a clear bullish purchase signal.

Key Details

• Transaction dates: August 14, 2026 (PSU settlement and issuer-mandated tax sale); August 18, 2026 (open-market sales). Filing date: August 18, 2026 (timely filed).
• Open-market sale prices and ranges: 11,930 shares at weighted avg $32.01 (individual trades ranged $31.40–$32.36); 637 shares at weighted avg $32.47 (range $32.44–$32.54). Reporting shows open-market proceeds ≈ $402,528.
• PSU settlement: 26,250 shares reported acquired (conversion of performance stock units) on 8/14/2026; an issuer-mandated sale of 26,250 shares was reported to satisfy tax withholding (footnote).
• Shares owned after the transactions: not specified in the filing.
• Notable footnotes: F1 = issuer-mandated sale to satisfy tax withholding; F2/F3 = reported prices are weighted averages over multiple trades (ranges provided); F4/F5 = each PSU equals one share and the award achievement/vesting schedule is documented (achievement certified Aug 14, 2025; half vested Aug 14, 2025 and remainder vested Aug 14, 2026 subject to continued service).

Context

• The filing shows conversion/settlement of PSUs followed by an issuer-mandated sale to cover taxes and separate open-market sales a few days later. When insiders sell shares tied to compensation vesting and tax-withholding, these are typically routine transactions rather than purchases that might signal increased insider confidence.